TWI366461B - Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor - Google Patents

Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Info

Publication number: TWI366461B
Authority: TW; Taiwan
Prior art keywords: receptor; compounds; fused compounds; subtype; inhibit vanilloid
Prior art date: 2003-06-12

Application number

TW099119548A

Other languages

English (en)

Other versions

TW201038269A (en

Inventor

Arthur Gomtsyan

Erol K Bayburt

Chih-Hung Lee

John R Koenig

Robert Schmidt

Kirill Lukin

Gilles Chambournier

Margaret Hsu

M Robert Leanna

Russel D Cink

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-12

Filing date

2004-06-14

Publication date

2012-06-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI366461(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-06-12 Priority claimed from US10/459,925 external-priority patent/US7015233B2/en

2004-06-09 Priority claimed from US10/864,068 external-priority patent/US7375126B2/en

2004-06-14 Application filed by Abbott Lab filed Critical Abbott Lab

2010-11-01 Publication of TW201038269A publication Critical patent/TW201038269A/zh

2012-06-21 Application granted granted Critical

2012-06-21 Publication of TWI366461B publication Critical patent/TWI366461B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Materials For Photolithography (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

TW099119548A 2003-06-12 2004-06-14 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor TWI366461B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/459,925 US7015233B2 (en)	2003-06-12	2003-06-12	Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US10/864,068 US7375126B2 (en)	2003-06-12	2004-06-09	Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Publications (2)

Publication Number	Publication Date
TW201038269A TW201038269A (en)	2010-11-01
TWI366461B true TWI366461B (en)	2012-06-21

Family

ID=33555102

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
TW101107398A TW201300361A (zh)	2003-06-12	2004-06-14	抑制香草類化物受體（ｖａｎｉｌｌｏｉｄｒｅｃｅｐｔｏｒ）次型１（ｖｒ１）受體之稠合化合物
TW093117059A TWI394569B (zh)	2003-06-12	2004-06-14	抑制香草類化物受體（ｖａｎｉｌｌｏｉｄｒｅｃｅｐｔｏｒ）次型１（ｖｒ１）受體之稠合化合物
TW099119548A TWI366461B (en)	2003-06-12	2004-06-14	Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
TW101107398A TW201300361A (zh)	2003-06-12	2004-06-14	抑制香草類化物受體（ｖａｎｉｌｌｏｉｄｒｅｃｅｐｔｏｒ）次型１（ｖｒ１）受體之稠合化合物
TW093117059A TWI394569B (zh)	2003-06-12	2004-06-14	抑制香草類化物受體（ｖａｎｉｌｌｏｉｄｒｅｃｅｐｔｏｒ）次型１（ｖｒ１）受體之稠合化合物

Country Status (20)

Country	Link
EP (2)	EP2017265B1 (zh)
JP (2)	JP4857113B2 (zh)
KR (2)	KR101138216B1 (zh)
CN (1)	CN102617464A (zh)
AT (2)	ATE411982T1 (zh)
AU (2)	AU2004247721C1 (zh)
BR (1)	BRPI0411116A (zh)
CA (2)	CA2756058A1 (zh)
CY (2)	CY1108713T1 (zh)
DE (1)	DE602004017329D1 (zh)
DK (2)	DK1658269T3 (zh)
ES (1)	ES2318308T3 (zh)
IL (4)	IL172457A (zh)
MX (1)	MXPA05013550A (zh)
NZ (3)	NZ578264A (zh)
PL (2)	PL2017265T3 (zh)
PT (2)	PT1658269E (zh)
SI (2)	SI1658269T1 (zh)
TW (3)	TW201300361A (zh)
WO (1)	WO2004111009A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050026844A1 (en)	2003-04-03	2005-02-03	Regents Of The University Of California	Inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en)	2004-03-16	2009-04-29	Univ California	REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
WO2006045119A2 (en)	2004-10-20	2006-04-27	The Regents Of The University Of California	Improved inhibitors for the soluble epoxide hydrolase
CA2589274A1 (en)	2004-12-07	2006-06-15	Locus Pharmaceuticals, Inc.	Inhibitors of protein kinases
EP1828169A2 (en)	2004-12-07	2007-09-05	Locus Pharmaceuticals, Inc.	Urea inhibitors of map kinases
CA2624307C (en)	2005-10-07	2014-04-29	Glenmark Pharmaceuticals S.A.	Substituted benzofused derivatives and their use as vanilloid receptor ligands
US20070104780A1 (en) *	2005-10-25	2007-05-10	Lipari John M	Formulation comprising a drug of low water solubility and method of use thereof
KR20080067361A (ko)	2005-10-28	2008-07-18	아보트 러보러터리즈	Ｔｒｐｖ1 수용체를 억제하는 인다졸 유도체
AR059826A1 (es)	2006-03-13	2008-04-30	Univ California	Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
KR20080111144A (ko) *	2006-04-18	2008-12-22	아보트 러보러터리즈	바닐로이드 수용체 서브타입 １(ｖｒ１)의 길항제 및 이의 용도
WO2009081222A1 (en)	2007-12-21	2009-07-02	Glenmark Pharmaceuticals, S.A.	Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
EP2238105B1 (en)	2008-01-28	2014-04-16	Amorepacific Corporation	Novel compounds as vanilloid receptor antagonists
WO2010002209A2 (en)	2008-07-02	2010-01-07	Amorepacific Corporation	Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
US8604053B2 (en) *	2008-10-17	2013-12-10	Abbvie Inc.	TRPV1 antagonists
EP2528604B1 (en)	2010-01-29	2017-11-22	The Regents of the University of California	Acyl piperidine inhibitors of soluble epoxide hydrolase
CN108329246B (zh)	2011-05-13	2021-02-26	阵列生物制药公司	作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
CN104364236B (zh) *	2012-05-09	2018-01-16	拜尔农作物科学股份公司	5‑卤代吡唑二氢茚基甲酰胺
WO2014078417A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078408A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078322A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
AU2013344943B2 (en)	2012-11-13	2017-06-29	Array Biopharma Inc.	N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078378A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790178B2 (en)	2012-11-13	2017-10-17	Array Biopharma Inc.	Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CN104903310B (zh)	2012-11-13	2018-08-14	阵列生物制药公司	可用于治疗疼痛的双环脲、硫脲、胍及氰基胍化合物
WO2014078328A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9969694B2 (en)	2012-11-13	2018-05-15	Array Biopharma Inc.	N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US10835533B2 (en)	2014-05-15	2020-11-17	Array Biopharma Inc.	1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor
AU2017257151A1 (en) *	2016-04-29	2018-11-15	Board Of Regents, The University Of Texas System	Sigma receptor binders
DE102022104759A1 (de)	2022-02-28	2023-08-31	SCi Kontor GmbH	Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW536734B (en) *	2000-07-31	2003-06-11	Clariant Int Ltd	Process for manufacturing a microelectronic device
EP1414788A1 (en) *	2001-07-31	2004-05-06	Bayer HealthCare AG	Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
JP2003192587A (ja) *	2001-12-26	2003-07-09	Bayer Ag	尿素誘導体
EP1478363B1 (en) *	2002-02-20	2009-01-14	Abbott Laboratories	Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
GB0206876D0 (en) *	2002-03-22	2002-05-01	Merck Sharp & Dohme	Therapeutic agents
EP1506166B1 (en) *	2002-05-17	2011-11-16	Janssen Pharmaceutica NV	Aminotetralin-derived urea modulators of vanilloid vr1 receptor

2004
- 2004-06-10 DE DE602004017329T patent/DE602004017329D1/de not_active Expired - Lifetime
- 2004-06-10 ES ES04754996T patent/ES2318308T3/es not_active Expired - Lifetime
- 2004-06-10 MX MXPA05013550A patent/MXPA05013550A/es active IP Right Grant
- 2004-06-10 EP EP08166079A patent/EP2017265B1/en not_active Expired - Lifetime
- 2004-06-10 CA CA2756058A patent/CA2756058A1/en not_active Abandoned
- 2004-06-10 AT AT04754996T patent/ATE411982T1/de active
- 2004-06-10 SI SI200430995T patent/SI1658269T1/sl unknown
- 2004-06-10 PL PL08166079T patent/PL2017265T3/pl unknown
- 2004-06-10 AU AU2004247721A patent/AU2004247721C1/en not_active Ceased
- 2004-06-10 NZ NZ578264A patent/NZ578264A/en not_active IP Right Cessation
- 2004-06-10 WO PCT/US2004/018590 patent/WO2004111009A1/en not_active Ceased
- 2004-06-10 NZ NZ543713A patent/NZ543713A/en not_active IP Right Cessation
- 2004-06-10 KR KR1020057023829A patent/KR101138216B1/ko not_active Expired - Fee Related
- 2004-06-10 EP EP04754996A patent/EP1658269B1/en not_active Expired - Lifetime
- 2004-06-10 SI SI200431715T patent/SI2017265T1/sl unknown
- 2004-06-10 DK DK04754996T patent/DK1658269T3/da active
- 2004-06-10 AT AT08166079T patent/ATE510824T1/de active
- 2004-06-10 CN CN2012100573625A patent/CN102617464A/zh active Pending
- 2004-06-10 PT PT04754996T patent/PT1658269E/pt unknown
- 2004-06-10 NZ NZ590234A patent/NZ590234A/en not_active IP Right Cessation
- 2004-06-10 BR BRPI0411116-8A patent/BRPI0411116A/pt not_active IP Right Cessation
- 2004-06-10 KR KR1020117017610A patent/KR101150324B1/ko not_active Expired - Fee Related
- 2004-06-10 CA CA2526872A patent/CA2526872C/en not_active Expired - Fee Related
- 2004-06-10 PT PT08166079T patent/PT2017265E/pt unknown
- 2004-06-10 DK DK08166079.7T patent/DK2017265T3/da active
- 2004-06-10 JP JP2006533722A patent/JP4857113B2/ja not_active Expired - Fee Related
- 2004-06-10 PL PL04754996T patent/PL1658269T3/pl unknown
- 2004-06-14 TW TW101107398A patent/TW201300361A/zh unknown
- 2004-06-14 TW TW093117059A patent/TWI394569B/zh not_active IP Right Cessation
- 2004-06-14 TW TW099119548A patent/TWI366461B/zh not_active IP Right Cessation
2005
- 2005-12-08 IL IL172457A patent/IL172457A/en not_active IP Right Cessation
2009
- 2009-01-14 CY CY20091100044T patent/CY1108713T1/el unknown
2010
- 2010-08-01 IL IL207335A patent/IL207335A/en not_active IP Right Cessation
- 2010-12-17 AU AU2010257277A patent/AU2010257277B2/en not_active Ceased
2011
- 2011-03-07 JP JP2011049274A patent/JP2011153148A/ja active Pending
- 2011-07-28 CY CY20111100738T patent/CY1111945T1/el unknown
- 2011-10-27 IL IL215997A patent/IL215997A0/en unknown
- 2011-10-30 IL IL216046A patent/IL216046A0/en unknown

Also Published As

Publication number	Publication date
KR20060058769A (ko)	2006-05-30
MXPA05013550A (es)	2006-04-05
NZ590234A (en)	2012-07-27
NZ578264A (en)	2011-02-25
CA2526872A1 (en)	2004-12-23
AU2010257277B2 (en)	2011-08-18
JP4857113B2 (ja)	2012-01-18
HK1093727A1 (zh)	2007-03-09
HK1126488A1 (zh)	2009-09-04
PL2017265T3 (pl)	2011-11-30
JP2011153148A (ja)	2011-08-11
ATE411982T1 (de)	2008-11-15
CA2526872C (en)	2013-02-05
PT2017265E (pt)	2011-07-29
ATE510824T1 (de)	2011-06-15
EP1658269A1 (en)	2006-05-24
PT1658269E (pt)	2009-01-09
AU2004247721B2 (en)	2011-01-20
CY1108713T1 (el)	2014-04-09
CA2756058A1 (en)	2004-12-23
DK1658269T3 (da)	2009-01-12
WO2004111009A1 (en)	2004-12-23
NZ543713A (en)	2009-08-28
TWI394569B (zh)	2013-05-01
SI2017265T1 (sl)	2011-09-30
KR20110089464A (ko)	2011-08-08
KR101150324B1 (ko)	2012-06-13
EP2017265A1 (en)	2009-01-21
ES2318308T3 (es)	2009-05-01
JP2007500753A (ja)	2007-01-18
IL207335A0 (en)	2010-12-30
AU2004247721A1 (en)	2004-12-23
DK2017265T3 (da)	2011-09-19
IL207335A (en)	2012-02-29
IL215997A0 (en)	2011-12-29
SI1658269T1 (sl)	2009-04-30
TW201038269A (en)	2010-11-01
PL1658269T3 (pl)	2009-08-31
CY1111945T1 (el)	2015-11-04
DE602004017329D1 (de)	2008-12-04
IL216046A0 (en)	2011-12-29
IL172457A (en)	2011-12-29
CN102617464A (zh)	2012-08-01
TW200509926A (en)	2005-03-16
BRPI0411116A (pt)	2006-07-18
EP2017265B1 (en)	2011-05-25
AU2010257277A1 (en)	2011-01-13
IL172457A0 (en)	2006-04-10
KR101138216B1 (ko)	2012-09-05
TW201300361A (zh)	2013-01-01
EP1658269B1 (en)	2008-10-22
AU2004247721C1 (en)	2011-12-22

Publication	Publication Date	Title
IL207335A0 (en)	2010-12-30	Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
IL173269A0 (en)	2006-06-11	Compounds for inflammation and immune-related uses
AU2003259747A8 (en)	2004-03-11	Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
TW200621232A (en)	2006-07-01	Compounds for inflammation and immune-related uses
EP1072592A3 (en)	2001-02-07	4-arylpiperidine derivatives for the treatment of pruritus
WO2004020431A3 (en)	2004-05-13	Novel benzoimidazole derivatives useful as antiproliferative agents
MY128063A (en)	2007-01-31	Aromatic heterocyclic compound as antiinflammatory agents
EP1467982B8 (en)	2007-04-11	Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
IS6275A (is)	2002-02-18	Heteróhringa efnasambönd og notkun þeirra sem mótlyf efnaskiptaglútamatviðtaka
WO2006062981A3 (en)	2007-02-22	Antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof
AU2002321910A1 (en)	2003-02-17	Pyrazole-derived kinase inhibitors and uses thereof
PL1689387T3 (pl)	2012-02-29	Bicykliczne inhibitory MEK i sposoby ich otrzymywania
MXPA04006031A (es)	2004-09-27	Compuestos para el tratamiento de trastornos inflamatorios.
WO2005040121A3 (en)	2005-06-23	Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
WO2006063178A3 (en)	2006-08-24	Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (vr1) and uses thereof
WO2005056535A8 (en)	2006-06-15	1,2,3-triazole amide derivatives as inhibitors of cytokine production
MX2007007100A (es)	2007-06-22	Benzisotiazol-1,1-dioxido que actua como antagonistas para el subtipo 1 del receptor de vanilloida (vr1) y usos de los mismos.
MXPA04005988A (es)	2004-09-27	3,4-dihidro-1h-isoquinolin-2-il-derivados.
WO2006029210A3 (en)	2006-05-04	Acyclic 1,3-diamines and uses therefor

Legal Events

Date	Code	Title	Description
2015-03-21	MM4A	Annulment or lapse of patent due to non-payment of fees